Synonyms
- Antigenic Factor VIII
- CRM Assay
- vWF Antigen
Special Instructions
If the patient's hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted. Refer to Coagulation Collection Procedures for directions.
Expected Turnaround Time
1 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
For more information, please view the literature below.
Procedures for Hemostasis and Thrombosis: A Clinical Test Compendium
Specimen Requirements
Specimen
Plasma, frozen
Volume
1 mL
Container
Blue-top (sodium citrate) tube
Collection
Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.1 Evacuated collection tubes must be filled to completion to ensure a proper blood-to-anticoagulant ratio.2,3 The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood. A discard tube is not required prior to collection of coagulation samples unless the sample is collected using a winged (butterfly) collection system. With a winged blood collection set a discard tube should be drawn first to account for the dead space of the tubing and prevent under-filling of the evacuated tube.4,5 When noncitrate tubes are collected for other tests, collect sterile and nonadditive (red-top) tubes prior to citrate (blue-top) tubes. Any tube containing an alternative anticoagulant should be collected after the blue-top tube. Gel-barrier tubes and serum tubes with clot initiators should also be collected after the citrate tubes.
Please print and use the Volume Guide for Coagulation Testing to ensure proper draw volume.
Storage Instructions
Freeze.
Stability Requirements
Temperature | Period |
|---|---|
Frozen | 28 days |
Freeze/thaw cycles | Stable x3 |
Patient Preparation
Avoid warfarin (Coumadin®) therapy for two weeks and heparin therapy for two days prior to the test. Do not draw from an arm with a heparin lock or heparinized catheter.
Causes for Rejection
Gross hemolysis; clotted specimen; frozen specimen thawed in transit; improper labeling
Test Details
Use
This test is used to diagnose von Willebrand factor (vWF) deficiency.6,8-10
Limitations
A number of transient clinical conditions can raise the vWF levels of individuals with congenital deficiency into the normal range.8 vWF is an acute phase reactant and levels can increase due to stress, inflammation, acute infection, physical exercise, and following surgery.8 Levels can also increase with estrogen administration for contraception or hormone replacement.8 vWF levels are increased two- to threefold in the second and third trimesters of pregnancy.10 Individuals with type O blood tend to have approximately 30% lower vWF levels than those with other blood types.10
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
This assay measures the total vWF protein level, independent of the multimer composition of the plasma.11 In this latex immunoagglutination assay (LIA), patient plasma is mixed with vWF antibody-coated latex particles. Aggregation of the latex particles caused by vWF from the sample is measured photo-optically.
Reference Interval
50% to 150%. Average vWF levels (both antigen and activity) tend to vary by blood type.6 One study found the mean vWF levels by blood type to be as follows:7
• Type O: 74.8%
• Type A: 105.6%
• Type B: 116.9%
• Type AB: 123.3%
Additional Information
See von Willebrand Factor (vWF) Profile [084715] for more clinical information.
Footnotes
1. Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol. 1997; 107(1):105-110. 8980376
2. Reneke J, Etzell J, Leslie S, et al. Prolonged prothrombin time and activated partial thromboplastin time due to underfilled specimen tubes with 109 mmol/L (3.2%) citrate anticoagulant. Am J Clin Pathol. 1998; 109(6):754-757. 9620035
3. National Committee for Clinical Laboratory Standardization. Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline. 5th ed. Villanova, Pa:NCCLS; 2008. Document H21-A5:28(5).
4. Gottfried EL, Adachi MM. Prothrombin time and activated partial thromboplastin time can be performed on the first tube. Am J Clin Pathol. 1997; 107(6):681-683. 9169665
5. McGlasson DL, More L, Best HA, et al. Drawing specimens for coagulation testing: Is a second tube necessary? Clin Lab Sci. 1999; 12(3):137-139. 10539100
6. Van Cott EM, Laposata M. Coagulation. In Jacobs DS, DeMott WR, Oxley DK eds. Laboratory Test Handbook With Key Word Index. Hudson, Ohio: Lexi-Comp; 2001: 327-358.
7. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987; 69(6):1691-1695. 3495304
8. Adcock DM, Bethel MA, Macy PA. Coagulation Handbook. Aurora, Colo: Esoterix−Colorado Coagulation; 2006.
9. Brandt JT. Laboratory Evaluation of Platelet Disorders. In McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2002:1010-1032.
10. Rick ME. von Willebrand Disease. In Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders Co; 2002: 91-102.
11. Liu MC, Kessler CM. A systemic approach to the bleeding patient. In Kitchens CS, Alving BM, Kessler CM eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders Co; 2002:181-196.
References
Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): Evidence-based diagnosis and management guideline, the National Heart, Lung, and Blood Institute (NHLB) Expert Panel report (USA). Haemophilia. 2008 Mar; 14(2):171-232. 18315614
Tefferi A, Nichols WL. Acquired von Willebrand disease: Concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997 Dec; 103(6):536-540. 9428838
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 086280 | von Willebrand Factor (vWF) Ag | 27816-8 | 086280 | von Willebrand Factor (vWF) Ag | % | 27816-8 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf